Mote Therapeutics
Founded in 2023 and headquartered in Lexington, Mote was created by Fapon Group and Alex Wesselhoeft. Its mobilize platform enables targeted LNP/circRNA delivery. Its BIO 2026 presentation identifies a preclinical CD19/BCMA in vivo CAR-T lead; a projected November IIT is not proof of dosing.
Corporate information
- Company entity
- Mote Therapeutics
- Headquarters / principal office
- Lexington, Massachusetts, United States ↗
- Founded
- 2023 ↗
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- https://www.motetx.com/press/1 ↗
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Founded in 2023 and headquartered in Lexington, Mote was created by Fapon Group and Alex Wesselhoeft. Its mobilize platform enables targeted LNP/circRNA delivery. Its BIO 2026 presentation identifies a preclinical CD19/BCMA in vivo CAR-T lead; a projected November IIT is not proof of dosing.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Mote Therapeutics and Axelyf Form Alliance to Provide Off-the-Shelf In Vivo T-Cell Targeted Delivery for Nucleic Acids
- Mote — Company-provided BIO 2026 presentation
- Mote — About Us